BELLEVUE, Wash., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Truveta announced today that Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 ...

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

While sky high expectations for Eli Lilly’s (NYSE: LLY) tirzepatide have not yet been realized, more positive data add to a ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...